About ACTEMRA and RA
ACTEMRA® (tocilizumab) was the first RA treatment to directly block the action of a protein in your body called interleukin-6 (IL-6). This protein is believed to play a part in RA.
ACTEMRA® (tocilizumab) was the first RA treatment to directly block the action of a protein in your body called interleukin-6 (IL-6). This protein is believed to play a part in RA.
IL-6 connects to the cell and tells the cell to activate. When the cell activates, it may contribute to the signs and symptoms of RA.
ACTEMRA blocks IL-6 from
connecting to the cell.
The way ACTEMRA is believed to work was suggested in preclinical research. It is not known exactly how it works in the body.
If you have diverticulitis (inflammation in parts of the large intestine), talk to your healthcare provider before taking ACTEMRA. Some people taking ACTEMRA may develop a hole in the wall of their stomach or intestines (also known as a perforation). This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate.
Tell your healthcare provider right away if you see any of these side effects: fever, stomach-area pain that does not go away, or if you see a change in your bowel habits.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.